CT-388: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •6 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
CT-388 is not approved by any regulatory authority. It is in Phase 2 clinical trials with Phase 3 planned for Q1 2026. The full safety profile has not yet been established.
As a GLP-1 receptor agonist, CT-388 is expected to carry the GLP-1 class warning for thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with MTC or MEN2 history.
GI adverse events are the most common side effects. In Phase 1b, 83.3% experienced GI-related TEAEs. Most were mild to moderate. Discontinuation due to AEs was 5.9% in Phase 2.
The signal-biased mechanism (minimal beta-arrestin recruitment) is novel. Long-term consequences of sustained biased signaling at GLP-1R and GIPR are not fully characterized.
GLP-1 receptor agonists are associated with pancreatitis risk. Patients should report persistent severe abdominal pain immediately.
Substantial weight loss (22.5% at 48 weeks) increases the risk of cholelithiasis and cholecystitis.
⚠️Important Warnings
- •INVESTIGATIONAL AGENT: CT-388 is not approved by any regulatory authority. It should only be used within approved clinical trials.
- •EXPECTED GLP-1 CLASS WARNING: CT-388 is expected to carry the thyroid C-cell tumor warning. Do not use in patients with MTC or MEN2 history.
- •GI adverse events are very common (83.3% in Phase 1b). Most are mild to moderate. Maintain adequate hydration.
- •NOVEL MECHANISM: The signal-biased agonism (minimal beta-arrestin) is a novel pharmacological approach. Long-term effects are unknown.
- •Do not use during pregnancy. GLP-1 receptor agonists should be discontinued before planned conception.
- •No cardiovascular outcomes data are available. Long-term cardiovascular safety has not been established.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Phase 2 completed. Phase 3 planned for Q1 2026. Not FDA-approved. |
| European Union | Investigational | Not EMA-approved. Regulatory pathway anticipated following Phase 3. |
| United Kingdom | Investigational | Not MHRA-approved. No regulatory submission. |
| Canada | Investigational | Not Health Canada-approved. No regulatory submission. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
CT-388 is an investigational signal-biased dual GLP-1/GIP receptor agonist currently in Phase 2 clinical development. It has not been approved by any regulatory authority. Safety data are derived from Phase 1b and Phase 2 trials enrolling approximately 500 patients with a maximum treatment duration of 48 weeks.
Investigational Status#
CT-388 is in early-mid stage development:
- Phase 2: Completed in 469 patients over 48 weeks
- Phase 3: Two trials planned for Q1 2026
- No NDA filed: Regulatory filing several years away
- SC only: No oral formulation in development
Until regulatory approval, CT-388 should only be used within approved clinical trials.
Novel Mechanism Risks#
CT-388's signal-biased mechanism represents a novel pharmacological approach. While the minimal beta-arrestin recruitment may theoretically reduce receptor desensitization, the long-term consequences of sustained biased signaling at both GLP-1R and GIPR are not fully understood:
- Beta-arrestin signaling serves biological functions beyond receptor internalization (scaffolding, ERK signaling)
- Chronic reduction of beta-arrestin-mediated pathways may have unanticipated long-term effects
- No long-term data beyond 48 weeks are available
GLP-1/GIP Agonist Class Risks#
Thyroid C-Cell Tumors#
GLP-1 receptor agonists carry a class-wide boxed warning based on thyroid C-cell tumors observed in rodent studies. CT-388 is expected to carry similar warnings and contraindications for MTC/MEN2.
Pancreatitis#
GLP-1 agonists have been associated with pancreatitis risk. Patients should report persistent severe abdominal pain.
Gallbladder Disease#
The substantial weight loss produced by CT-388 (22.5% at 48 weeks) increases the risk of cholelithiasis and cholecystitis.
Acute Kidney Injury#
GI adverse events may cause dehydration, which could contribute to acute kidney injury.
Safety Database#
| Parameter | Current Data |
|---|---|
| Phase 1b patients | Small (exact N not disclosed) |
| Phase 2 patients | 469 |
| Maximum treatment duration | 48 weeks |
| Discontinuation due to AEs | 5.9% (CT-388) vs 1.3% (placebo) |
| Serious adverse events | No signals reported |
| CV outcomes data | None |
Regulatory and Legal Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (FDA) | Investigational | Phase 2 completed; Phase 3 planned Q1 2026 |
| European Union (EMA) | Investigational | No regulatory submission |
| United Kingdom (MHRA) | Investigational | No regulatory submission |
| Canada (Health Canada) | Investigational | No regulatory submission |
At-Risk Populations#
Patients with MTC or MEN2 History#
Expected absolute contraindication based on GLP-1 agonist class labeling.
Pregnant and Breastfeeding Women#
GLP-1 receptor agonists carry pregnancy risks. Discontinue before planned conception.
Patients with Severe GI Disease#
GI adverse events may be poorly tolerated by patients with gastroparesis or GI motility disorders.
Patients on Insulin or Sulfonylureas#
GLP-1 receptor agonism may increase hypoglycemia risk when combined with insulin.
Risk Mitigation#
- Use only within approved clinical trials
- Screen for MTC/MEN2 history
- Follow dose escalation schedule
- Maintain adequate hydration
- Monitor for pancreatitis and gallbladder symptoms
- Adjust insulin or sulfonylurea doses when initiating treatment
Related Reading#
Frequently Asked Questions About CT-388
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.